In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.


on Dyslipidaemias


Atherosclerotic cardiovascular disease is the most common cause of deaths globally. The primary event instigating atherogenesis is the retention of low-density lipoprotein cholesterol (LDL-C) within the arterial wall. Clinical trials have firmly established that lowering plasma LDL-C has beneficial effects on the prognosis of cardiovascular diseases, and that there is no lower limit of LDL-C known to be unsafe. The 2019 ESC/EAS Guidelines for the management of dyslipidaemias have established the definite causality of LDL-C in atherosclerotic cardiovascular diseases and have incorporated the use of novel treatments.

This issue of FOCUS was curated by Ronen Beeri, Colin Baigent and François Mach to help expand knowledge on dyslipidaemias. 




Risk assessment and lipid management in primary prevention
11 April 2024
With François Mach, Monika Hollander, Frank Lj Visseren

Unmet needs in lipid management: treatment goals and how to achieve them
15 April 2024
With Konstantinos Koskinas, Florian Kronenberg, Charalambos Vlachopoulos

New trial evidence in the field of lipid management
19 April 2024
With Lale Takgozoglu, Victor Aboyans, Ulf Landmesser


Dig deeper

Exclusive for members

Discover all FOCUS editions